Infections caused by Mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation

Frontiers in Oncology

Volumn 4 AUG, Issue , 2014, Pages

  Al Anazi, Khalid Ahmed ^a   Al Jasser, Asma Marzouq ^b   Alsaleh, Khalid ^a  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b MINISTRY OF HEALTH   (Saudi Arabia)

Author keywords

Drug resistance; Hematological malignancy; Hematopoietic stem cell transplantation; Latency; Mycobacterium tuberculosis

Indexed keywords

BCG VACCINE; BEDAQUILINE; BUSULFAN; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DELAMANID; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; SUTEZOLID;

ALLOGRAFT; ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; RISK FACTOR; TUBERCULOSIS; VACCINATION;

EID: 84906255784     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00231     Document Type: Article

References (99)

1. Al-Anazi KA, Al-Jasser AM. Tuberculosis in the era of globalization. OMICS Group e Books (2013) www.esciencecentral.org/ebooks.
2. Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy (2012): 1-7.
3. Halse TA, Escuyer VE, Musser KA. Evaluation of a single-tube multiplex real-time PCR for differentiation of members of the Mycobacterium tuberculosis complex in clinical specimens. J Clin Microbiol (2011) 49: 2562-2567.
4. Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, et al. A systemic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess (2007) 11: 1-196.
5. Al-Anazi KA, Al-Jasser AM, Evans DAP. Infections caused by Mycobacterium tuberculosis in patients with hematological disorders and in recipients of hematopoietic stem cell transplantation: a twelve year retrospective study. Ann Clin Microbiol Antimicrob (2007) 6:16.
6. MunsiffS, Nilsen D, DworKin F. Guidelines for testing and treatment of latent tuberculosis infection. NYC Department of Health and Mental Hygiene. Bureau of tuberculosis Control (2005): 1-12.
7. Anibarro L, Pena A. Tuberculosis in patients with hematological malignancies. Mediterr J Hematol Oncol (2014) 6 (1): e2014026, doi: 10.4048/MJHID.2014.026.
8. Fanning EA. Globalization of tuberculosis. Can Med Assoc J (1998) 158: 611-612.
9. Selgelid MJ. Ethics, tuberculosis and Globalization. Public Health Ethics (2008) 1: 10-20.
10. Oza S. Tuberculosis: an overlooked global threat. Massachusetts Undergrad Res J (2008) 6: 25-29.
11. Tombolyn M, Chiller T, Eisele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infections complications among hematopoietic stem cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant (2009) 15: 1143-1238.
12. Erdstein AA, Daas P, Bradstock KF, Robinson T, Hertzberg MS. Tuberculosis in allogeneic stem cell transplant recipients: still a problem in the 21st century. Transpl Infect Dis (2004) 6 (4): 142-146.
13. Tomaszewska A, Nasilowska-Adamska B, Prochorec-Sobieszek M, Halaburda K, Szczepiński A, Mariańska B. Extrapulmonary tuberculosis following allogeneic stem cell transplantation-a difficult and late diagnosis. Arch Med Sci (2009) 5 (3): 489-491.
14. Ambrossi GG, Jakubowski A, Feinstein MB, Weinstock DM. Active tuberculosis limited to foreign-born patients after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant (2005) 36: 741-743.
15. Garcia-Elorriaga G, del Rey-Pineda G. Tuberculosis and hematopoietic stem cell transplant: review of a difficult and often underestimated problem. World J Clin Infect Dis (2013) 3 (4): 70-78.
16. Maeda T, Kusumi E, Kami M, Kawabata M, Le Pavoux A, Hara S, et al. Disseminated tuberculosis following reduced-intensity cord blood transplantation for adult patients with hematological diseases. Bone Marrow Transplant (2005) 35: 91-97.
17. Al-Anazi KA, Al-Jasser AM. Pulmonary mycobacterial infections in patients with hematological malignancies. In Pulmonary Involvement in patients with Hematological Malignancies (2011). Ist edn. Springer-Verlag Berlin and Heidelberg Gmb H & Co. KG. Germany. Pages 369-283.
18. Lee J, Lee MH, Kim WS, Kim K, Park SH, Lee SH, et al. Tuberculosis in hematopoietic stem cell transplant recipients in Korea. Int J Hematol (2004) 79 (2): 185-188.
19. de la Camara R, Martino R, Granados E, Rodriguez-Salvanės FJ, Rovira M, Cabrera R, et al. Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical features and outcome. Bone Marrow Transplant (2000) 26: 291-298.
20. Yuen KY, Woo PCY. Tuberculosis in blood and marrow transplant recipients. Hematol Oncol (2001) 20 (2): 51-62.
21. Ramos JF, Batista MV, Costa SF. Tuberculosis in hematopoitic stem cell transplant recipients. Mediterr J Hematol Infect Dis (2013) 5 (1): ė 201306, DOI: 10.4084/MJHID.2013.061.
22. IP MSM, Yuen KY, Woo PCY, Luk WK, Tsang KWT, Lam WK, et al. Risk factors for pulmonary tuberculosis in bone marrow transplant recipients. Am J Respir Crit Care Med (1998) 158: 1173-1177.
23. Lee HJ, Kwon JC, Kim SH, Park SH, Choi SM, Lee DG, et al. High incidence of tuberculosis among allogeneic stem cell transplant recipients in Korea. Abstract number 530. Poster Abstract session: Transplant and immunocompromised hosts, October 18, 2012. ID week.
24. George B, Mathews V, Srivastava V, Srivastava A, Chandy M. Tuberculosis among allogeneic bone marrow transplant recipients in India. Bone Marrow Transplant (2001) 27: 973-975.
25. Martino R, Martinez C, Brunet S, Sureda A, Lopez R, Domingo-Albós A. Tuberculosis in bone marrow transplant recipients: report of two cases and review of the literature. Bone Marrow Transplant (1996) 18 (4): 809-812.
26. De Assis RA, Kerbauty FR, Rodrigues M, Seguro FS, Aranha LFC, Fayad L, et al. Mycobacterium tuberculosis infection: a rare late complication after cord blood hematopoietic SCT. Bone Marrow Transplant (2008) 43: 667-668; doi:10.1038/bmt.2008.379; published online 24 November 2008.
27. Hughes WT. Mycobacterial infections in bone marrow transplant recipients. Biol Blood Marrow Transplant (2000) 6: 359-360.
28. Budak-Alpdogan T, Tangún Y, Kalayoglu-Besisk S, Ratip S, Akan H, Baslar Z, et al. The frequency of tuberculosis in adult allogeneic stem cell transplant recipients in Turkey. Biol Blood Marrow Transplant (2000) 6: 370-374.
29. Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. J Hosp Infect (2006) 62 (4): 421-426.
30. Kindler T, Schindel C, Brass U, Fischer T. Fatal sepsis due to Mycobacterium tuberculosis after allogeneic bone marrow transplantation. Bone Marrow Transplant (2001) 27: 217-218.
31. Dolai TK, Kumar R, Bhargava R, Mahapatra M, Mishra P, Seth T, et al. Multi-organ failure due to Mycobacterium tuberculosis and Aspergillus flavas infection after allogeneic bone marrow transplantation. Indian J Hematol Blood Transfus (2008) 24 (2): 78-80.
32. AlJurf M, Gyger M, Alrajhi A, Sahovic E, Chaudhri N, Musa M, et al. Mycobacterium tuberculosis infection in allogeneic bone marrow transplantation patients. Bone Marrow Transplant (1999) 24: 551-554.
33. Russo RL, Dulley FL, Suganuma L, Franca IL, Yasuda MA, Costa SF. Tuberculosis in hematopoietic stem cell transplant patients: case report and review of the literature. Int J Infect Dis (2010) 14 (Suppl 3): e 187-191.
34. Biral E, Faraci M, Lanino E, Morreale G, Giardino S, Moroni C, et al. Mycobacterium tuberculosis pneumonia and bacteremia after allogeneic hematopoietic stem cell transplant: report of an instructive pediatric case. New Microbiol (2012) 35 (3): 353-357.
35. Ku S-C, Tang J-L, Hseuh P-R, Luh K-T, Yu C-J, Yang P-C. Pulmonary tuberculosis in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant (2001) 27: 1293-1297.
36. Sharma SK, Argawal N, Mukherjee A, Seth T, Mishra P, Xess I, et al. Coexisting pulmonary tuberculosis and mucormycosis in a patient with aplastic anemia post allogeneic stem cell transplantation. Mediterr J Hematol Infect Dis (2011) 3: e 2011036. DOI. 10.4084/MJHID. 2011.0036.
37. Ullah K, Raza S, Ahmed P, Satti TM, I Kram A, Chaudhri Q-U-N, et al. Pulmonary tuberculosis in allogeneic stem cell transplant recipients. J Pak Med Assoc (2007) 57(11): 567-569.
38. Buyck HCE, Holliman R, Else J, O'Regan L, Willis F, Grubnic S, et al. An usual cause of acute abdomen following allogeneic transplantation: a zoonotic disease revisited. Bone Marrow Transplant (2008) 41: 1069-1070.
39. Campos A, Vaz CP, Campilho F, Morais A, Guimaràes MA, Lopes C, et al. Central nervous system (CNS) tuberculosis following allogeneic stem cell transplantation. Bone Marrow Transplant (2000) 25: 567-569.
40. Palma J, Catalán P, Mardones P, Santolaya ME. Mycobacterium tuberculosis infection in a pediatric patient who underwent a hematopoietic stem cell transplant. Rev Chilena Infectol (2013) 30 (2): 202-205.
41. Shima T, Yoshimoto G, Miyamoto T, Yoshida S, Kamezaki K, Takenaka K, et al. Disseminated tuberculosis following second unrelated cord blood transplantation for acute myeloid leukemia. Transpl Infect Dis (2009) 11 (1): 75-77.
42. Cordonnier C, Martino R, Trabasso P, Held TK, Akan H, Ward MS. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis (2004) 38: 1229-1236.
43. Iguchi T, Yokoyama K, Mitsuishi M, Chen CK, Ikeda Y. Okamoto S. Pulmonary tuberculosis and adenovirus-hemorrhagic cystitis after autologous peripheral blood stem cell transplantation for follicular lymphoma. Rinsho Ketsueki (2005) 46 (9): 1049-1054.
44. Kuan F-C, Lin PY, Hwang C-E, Lu C-H, Chen C-C. Pancytopenia and myeloid maturation arrest in an autologous stem cell transplant recipient. Bone Marrow Transplant (2011) 46: 610-611.
45. Altclas J, Lescano A, Salgueira C, Di Martino A, Brennan V, Campestri R et al. Multi-drug resistant tuberculosis in bone marrow transplant recipient. Transpl Infect Dis (2005) 7 (1): 46-46.
46. Lee JW, Kwon P-S, Chung N-G, Cho B, Jeong D-C, Kang J-H, et al. Two children with differing outcomes after treatment for pulmonary tuberculosis diagnosed after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis (2011) 13: 520-523.
47. Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J (2012) 40 (4): 990-1013.
48. Ahmed P, Anwar M, Khan B, Altaf C, Ullah K, Raza S, et al. Role of isoniazid prophylaxis for prevention of tuberculosis in hematopoietic stem cell transplant recipients. J Pak Med Assoc (2005) 55 (9): 378-381.
49. Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol (2010) 185: 15-22.
50. Miranda MS, Breiman A, Allain S, Deknuydt F, Altare F. The tuberculosis granuloma: an unsuccessful host defense mechanism providing a safety shelter for the bacteria? Clin Dev Immunol (2012) 2012:139127. doi: 10.1155/2012/139127. Epub 2012 Jul 3.
51. Chensue SW. Chemokines in innate and adaptive granuloma formation. Front Immunol (2013) 4 (43): 15-23.
52. Ufimtseva E. Investigation of functional activity of cells in granulomatous inflammatory lesions from mice with latent tuberculous infection in the new ex vivo model. Clin Dev Immunol (2013). 2013:371249. http://dx.doi.org/10.1155//2013/371249.Epub 2013 Oct 2.
53. Kapoor N, Pawar S, Sirakova TD, Deb C, Warren WL, Kolattukudy PE. Human granuloma in vitro model, for TB dormancy and resuscitation. PLoS ONE (2013) 8 (1) e 53657. doi:10.1371/journal.pone.0053657.
54. Ehlers S, Schaible UE. The granuloma in tuberculosis: dynamics of a host-pathogen collusion. Front Immunol (2013) 3 (411) doi:10.3389/fimmu. 2012. 00411. eCollection 2012.
55. Boros DL. New perspectives on ancient granulomas. Front Immunol (2013) 4 (345). doi:10.3389/fimmu. 2013. 00345. eCollection2013.
56. Shaler CR, Horvath CN, Jayanathan M, Xing Z. Within the enemy's camp: contribution of the granuloma to the dissemination, persistence and transmission of Mycobacterium tuberculosis. Front Immunol (2013) 4 (30). doi:10. 3389/fimmu. 2013.00030. eCollection 2013.
57. Guirado E, Schlensinger LS. Modeling the Mycobacterium tuberculosis granuloma-the critical battlefield in host immunity and disease. Front Immunol (2013) 4 (98). doi: 103389/fimmu.2013.00098. eCollection 2013.
58. Raghuranshi S, Sharma P, Singh S, Kaer LV, Das G. Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal cells. Proc Natl Acad Sci (2010) 107 (50): 21653-21658.
59. Mittal R. Mesenchymal stem cells: the new players in the pathogenesis of tuberculosis. J Microbial Biochem Technol (2011) 3:3. http://dx.doi.org/10.4172/1948-5948.100000e3.
60. Rai RC, Battacharya D, Das G. Stem cells in infectious diseases. In Insight and Control of Infectious Disease in Global Scenario. InTech (2012): edited by Roy Pritti. ISBN:971-953-51-0319-6. Available from: http://www.intechopen.com/books/insight-and-control-of-infectiousdisease-in-globalscenario/stem-cells-in-infectious-diseases.
61. Das B, Kashino SS, Pulu I, Kalita D, Swami V. Yeger H, et al. CD 271+ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci Transl Med (2013) 5 (170): 170ra 13. doi:10.1126/scitrans/med.3004912.
62. Bhattacharyya R, Shukla M, Nagra S, Banerjee D. Insights from the computational analysis of CD 271+ glycation in mesenchymal stem cells in diabetes mellitus as a predisposition to latent tuberculosis. Bioinformation (2013) 9 (16): 829-831.
63. Molicotti P, Bua A, Zanetti S. Cost-effectiveness in the diagnosis of tuberculosis: choices in developing countries. J Infect Dev Ctries (2014) 8 (1): 024-038.
64. Drobniewski F, Nikolayevsky V, Maxeiner H, Balabanova Y, Casali N, Kontsevaya I, et al. Rapid diagnosis of tuberculosis and drug resistance in the industrialized word: clinical and public health benefits and barriers to implementation. BMC Med (2013) 11:190. http://biomedcentral.com/174-7015/11/190.
65. Parsons LM, Somoskövi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev (2011) 24 (2): 314-350.
66. Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J (2005) 26 (2): 339-350.
67. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PloS Med (2011) 8 (11): e1001120.doi:10.1371/journal.pmed.1001120.
68. Balasingham SV, Davidsen T, Szpinda I, Frye SA, Tønjum T. Molecular diagnostics in tuberculosis: basis and implications for therapy. Mol Diagn Ther (2009) 13 (3): 137-151.
69. Tiwari D, Tiwari RP, Chandra R, Bisen PS, Haque S. Efficient ELISA for diagnosis of active tuberculosis employing a cocktail of secretory proteins of Mycobacterium tuberculosis. Folia Biol (Praha) (2014) 60: 10-20.
70. McNerney R, Maeurer M, Abubakar I, Marais B, Mchugh TD, Ford N, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances and opportunities. J Infect Dis (2012) S1-S12. DOI: 10.1093/infdis/jir 860.
71. Stolz D, Stulz A, Müller B, Gratwohl A, Tamm M. BAL neutrophils, serum prolactin and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest (2007) 132 (2): 504-514.
72. Jin M, Khan AI. Procalcitonin: uses in clinical laboratory for the diagnosis of sepsis. LabMedicine (2010) 41 (3): 173-177.
73. Zhang X, Guo J, Fan S, Li Y, Wei L, Yang X, et al. Screening and identification of six serum microRNAs as novel potential combination biomarkers for pulmonary tuberculosis diagnosis. PLoS ONE (2013) 8 (12): e 81076. doi:10.1371/journal.pone. 0081076.
74. Ruhwald M, Bodmer T, Maier C, Jepsen M, Haaland MB, Eugen-Oslen J, et al on behalf of TBNET. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur Respir J (2008) 32 (6): 1607-1615.
75. Qin L-L, Wang Q-R, Wang Q, Yao H, Wen L-T, Wu L-L, et al. T-SPOT.TB for detection of tuberculosis infection among hematological malignancy patients and hematopoietic stem cell transplantation recipients. Asian Pac J Cancer Prev (2013) 14 (12): 7415-7419.
76. Pai M, Menzies D. Interferon-gamma release assays for diagnosis of latent tuberculosis infection. UpToDate (Feb 2014): Pages 1-16.
77. Lee Y-M, Lee S-O, Choi S-H, Kim YS, Woo JH, Kim D-Y, et al. A prospective longitudinal study evaluating the usefulness of the interferongamma releasing assay for producing active tuberculosis in allogeneic hematopoietic stem cell transplantation recipients. J Infect (2014) 69 (2):165-73. doi: 10.1016/j.jinf.2014.02.019. Epub 2014 Mar 16.
78. Demirkazik FB, Akin A, Uzun ö, Akpinar MG, Ariyürek MO. CT findings in immunocompromised patients with pulmonary infections. Diagn Interv Radiol (2008) 14: 75-82.
79. Wingard JR, Hiemenz JW, Jantz MA. How I manage pulmonary nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. Blood (2012) 120: 1791-1800.
80. Kang M, Deoghuria D, Varma S, Gupta D, Bhatia A, Khandelwal N. Role of HRCT in detection and characterization of pulmonary abnormalities in patients with febrile neutropenia. Lung India (2013) 30 (2): 124-130.
81. Wang Z, Ning X. Clinical diagnosis of bacterial infection via FDG-PET imaging. Can Chem Trans (2013) 1 (2): 85-104.
82. Kumar R, Basu S, Torigian D, Anand V, Zhuang H, Alavi A. Role of modern imaging techniques for diagnosis of infection in the era of 18 f-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev (2008) 21 (1): 209-224.
83. Harkirat S, Anana SS, Indrajit LK, Dash AK. Pėctoral assay: PET/CT in tuberculosis. Indian J Radiol Imaging (2008) 18 (2): 141-147.
84. Zulma AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubaker I, et al. New antituberculosis drugs, regimens and adjunct therapies: needs, advances and future prospects. Lancet Infect Dis (2014) 14 (4): 327-340.
85. Okada M, Shirakawa T. Frontier of mycobacterium research-host vs. mycobacterium. Kekkaku (2005) 80 (9): 613-629.
86. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature (2011) 469: 483-490.
87. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multi-drug resistant tuberculosis. MMWR Recomm Rep (2013) 62 (RR-09): 1-12.
88. Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis (2012) 16 (8): 1005-1014.
89. Kwon YS, Jeong BH, Koh WJ. Tuberculosis: clinical trials and new drug regimens. Curr Opin Pulm Med (2014) 20 (3): 280-286.
90. Lin PL, Dartois V, Johnston PJ, Janssen C, Via L, Goodwin MB, et al. Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques. Proc Natl Acad Sci USA (2012) 109 (35): 14188-14193.
91. Uhlin M, Andersson J, Zumla A, Maeurer M. Adjunct immunotherapies for tuberculosis. J Infect Dis (2012) 205: S 325-S 334.
92. Erokhin VV, Vasil'eva IA, Konopliannikov AG, Chukanov VI, Tsyb AF, Bagdasarian TR, et al. Systemic transplantation of autologous mesenchymal stem cells of the bone marrow in the treatment of patients with multidrug-resistant pulmonary tuberculosis. Probl Tuberk Bolezn Legk (2008) 10: 3-6.
93. Skrahin A, Ahmed RK, Ferrara G, Rane L, Poiret T, Isaikina Y, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med (2014) 2: 108-122.
94. Liu J. New vaccine against tuberculosis: current development and future challenges. J Sci Foundation China (2009) 17 (2): 50-58.
95. Kaufmann SHE. Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect Dis (2011) 11: 633-640.
96. Kaufmann SHE, Lambert P-H. New vaccines for tuberculosis. Lancet (2010) 375: 2110-2119.
97. Kaufmann SHE, Lange C, Rao M, Balaji KN, Lotze M, Schito M, et al. Progress in tuberculosis vaccine development and host-directed therapies -a state of the art review. Lancet Respir Med (2014) 2 (4): 301-320.
98. OttenhoffTHM, Kaufmann SHE. Vaccines against tuberculosis: where are we and where we need to go? PLoS Pathogens (2012) 8 (5): e 1002607. doi:10.1371/journal.ppat.1002607.
99. Brennan MJ, Fruth U, Milstein J, Tiernan R, de Andrade Nishioka S, Chocarro L, et al and the Developing Countries Vaccine Regulatory Network and the Ad Hoc Regulatory and TB Expert Panel. Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med (2007) 4 (8): e 252. doi:10.1371/journal.pmed.0040252.